Harvard Catalyst Profiles
Contact, publication, and social network information about Harvard faculty and fellows.
Home
About
Overview
Open Source Software
Help
History (1)
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study.
See All Pages
Find People
Find Everything
Login
to
edit your profile
(add a photo, education, awards, etc.), search
student opportunities
, and
create reports
.
Edit My Profile
My Person List (
0
)
Opportunity Search
Return to Top
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study.
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study. Int J Cancer. 2014 Sep 01; 135(5):1247-56.
View in:
PubMed
subject areas
Adult
Aged
Antineoplastic Agents
Carcinoma, Hepatocellular
Cell Proliferation
Disease-Free Survival
Drug Resistance, Neoplasm
Female
Genotype
Humans
Liver Neoplasms
Lymphangiogenesis
Male
Middle Aged
Neovascularization, Pathologic
Niacinamide
Phenylurea Compounds
Polymorphism, Single Nucleotide
Protein Kinase Inhibitors
Retrospective Studies
Treatment Outcome
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factor C
Vascular Endothelial Growth Factor Receptor-1
Vascular Endothelial Growth Factor Receptor-2
Vascular Endothelial Growth Factor Receptor-3